A New Medicine to Treat Liver Disease (MASH)
TARGETING MASH WITH NOVEL SMALL MOLECULE TXNIP INHIBITOR
This work explores a new medicine called TIX100 to help people with a common liver condition called MASH, which currently has no approved treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11141184 on NIH RePORTER |
What this research studies
Our bodies have a protein called Txnip that can cause inflammation and damage in the liver, especially in conditions like MASH. We are developing a new small molecule medicine, TIX100, designed to block the effects of Txnip. This medicine has shown promising results in animal models, protecting against liver fat buildup, inflammation, and scarring. We aim to understand exactly how TIX100 works to improve liver health and metabolism.
Who could benefit from this research
Good fit: This foundational work is for patients with Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH), including those with obesity or diabetes.
Not a fit: Patients without MASLD or MASH, or those with other forms of liver disease, would likely not benefit directly from this specific treatment approach.
Why it matters
Potential benefit: If successful, this new medicine could offer the first approved treatment for MASH, potentially slowing or reversing liver damage for millions of people.
How similar studies have performed: While Txnip is known to contribute to liver disease, this specific small molecule inhibitor, TIX100, is a novel and untested approach in human clinical settings, though it has shown success in animal models.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Shalev, Anath — University of Alabama at Birmingham
- Study coordinator: Shalev, Anath
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.